Abstract | BACKGROUND: In recent years the number of studies on special tumor entities in the head and neck region has increased. During the 2021 meetings of the American Society of Clinical Oncology (ASMO) and the European Society for Medical Oncology (ESMO), several studies were presented which predict changes in clinical treatment algorithms for nasopharyngeal carcinoma, salivary gland, and thyroid cancer. OBJECTIVE: Future treatment alterations in specific head and neck tumor entities were evaluated after screening clinical studies presented at the 2021 ASCO and ESMO meetings. MATERIALS AND METHODS: A systematic analysis of the phase II and III clinical trials for nasopharyngeal carcinoma, salivary gland, and thyroid cancer treatment presented at ASCO and ESMO 2021 was performed. Taking into account current treatment standards, the results are structured in terms of their potential clinical significance. RESULTS AND CONCLUSION:
|
Authors | Henrike B Zech, Christian S Betz |
Journal | HNO
(HNO)
Vol. 70
Issue 4
Pg. 278-286
(Apr 2022)
ISSN: 1433-0458 [Electronic] Germany |
Vernacular Title | Spezielle Tumorentitäten im Kopf-Hals-Bereich : Nasopharynxkarzinom, Speicheldrüsenkarzinom und Schilddrüsenkarzinom. |
PMID | 35258645
(Publication Type: Journal Article, Review)
|
Copyright | © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. |
Chemical References |
- Iodine Radioisotopes
- Vascular Endothelial Growth Factor A
|
Topics |
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
(diagnosis, pathology, therapy)
- Salivary Glands
(pathology)
- Thyroid Neoplasms
(diagnosis, therapy)
- Vascular Endothelial Growth Factor A
(therapeutic use)
|